Si-bone, inc. receives fda 510(k) clearance for a smaller diameter ifuse bedrock granite implant with an expanded indication and application

Santa clara, calif., jan. 30, 2024 (globe newswire) -- si-bone, inc., (nasdaq: sibn), a silicon valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces fda 510(k) premarket clearance of the ifuse bedrock granite® implant system (granite) in a smaller (9.5 mm) diameter with both an expanded indication in pediatric patients and an expanded application that includes use in the s1 trajectory. when placed across the si joint, the granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for multi-segment spinal fusion.
SIBN Ratings Summary
SIBN Quant Ranking